{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T22:44:21Z","timestamp":1781909061940,"version":"3.54.5"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.diabres.2022.110144","type":"journal-article","created":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T17:47:46Z","timestamp":1667756866000},"page":"110144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Efficacy and safety of ultra-rapid insulin analogues in insulin pumps in patients with Type 1 Diabetes Mellitus: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"193","author":[{"given":"Athina","family":"Stamati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Karagiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos","family":"Tsapas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Christoforidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.diabres.2022.110144_b0005","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00592-019-01326-5","article-title":"Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials","volume":"56","author":"Pala","year":"2019","journal-title":"Acta Diabetol [Internet]"},{"key":"10.1016\/j.diabres.2022.110144_b0010","unstructured":"NICE. Insulin pump therapy for diabetes Understanding NICE guidance Information for people who use NHS services. Information about NICE technology appraisal guidance [Internet]. 2008;(July 2008). Available from: www.nice.org.uk\/aboutguidance."},{"issue":"3","key":"10.1016\/j.diabres.2022.110144_b0015","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2337\/ds18-0091","article-title":"A clinical overview of insulin pump therapy for the management of diabetes: Past, present, and future of intensive therapy","volume":"32","author":"Berget","year":"2019","journal-title":"Diabetes Spectrum"},{"issue":"9","key":"10.1016\/j.diabres.2022.110144_b0020","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1463-1326.2012.01580.x","article-title":"The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences","volume":"14","author":"Home","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2022.110144_b0025","volume":"44","author":"Committee for Medical","year":"2016","journal-title":"Production for Human Use. Fiasp, INN-insulin aspart"},{"key":"10.1016\/j.diabres.2022.110144_b0030","article-title":"Assessment report Lyumjev","volume":"31","year":"2020","journal-title":"International"},{"key":"10.1016\/j.diabres.2022.110144_b0035","unstructured":"US Food and Drug Administration Novo Nordisk. FIASP (insulin aspart) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/208751s010s011lbl.pdf."},{"key":"10.1016\/j.diabres.2022.110144_b0040","unstructured":"U.S. Food and Drug Administration. Eli Lilly and Company. Lyumjev (insulin lispro) [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761109s000lbl.pdf."},{"issue":"9","key":"10.1016\/j.diabres.2022.110144_b0045","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1111\/dom.13798","article-title":"Use of fast-acting insulin aspart in insulin pump therapy in clinical practice","volume":"21","author":"Evans","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2022.110144_b0050","unstructured":"Linnebjerg H, LaBell ES, Dellva MA, Lim S, Coutant DE, Leohr J. A new concentratedU-200 formulation ofUltra Rapid Lispro (URLi) demonstrated bioequivalence to URLi U-100. Diabetologia. 2020;63 (SUPPL 1):S326\u2010."},{"issue":"4","key":"10.1016\/j.diabres.2022.110144_b0055","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/dom.13610","article-title":"A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (ONSET 5)","volume":"21","author":"Klonoff","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.diabres.2022.110144_b0060","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1111\/dom.14368","article-title":"Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2","volume":"23","author":"Warren","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.diabres.2022.110144_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.diabres.2022.110144_b0070","unstructured":"Rohatgi A. WebPlotDigitizer Pacifica, California, USA 2021; 2021 [07\/11\/2021]. Version: 4.5. Available from: https:\/\/automeris.io\/WebPlotDigitizer."},{"key":"10.1016\/j.diabres.2022.110144_b0075","first-page":"1","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"The BMJ"},{"key":"10.1016\/j.diabres.2022.110144_b0080","unstructured":"Page MJ, Higgins JPT, Sterne JAC Chapter 13: Assessing risk of bias due to missing results in synthesis. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane; 2022."},{"issue":"1","key":"10.1016\/j.diabres.2022.110144_b0085","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1164","article-title":"Methods to estimate the between-study variance and its uncertainty in meta-analysis","volume":"7","author":"Veroniki","year":"2016","journal-title":"Res Synth Methods"},{"issue":"4","key":"10.1016\/j.diabres.2022.110144_b0090","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.diabres.2022.110144_b0095","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/1932296817730375","article-title":"Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes","volume":"12","author":"Zijlstra","year":"2018","journal-title":"J Diabetes Sci Technol"},{"issue":"4","key":"10.1016\/j.diabres.2022.110144_b0100","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1089\/dia.2020.0500","article-title":"Fast Acting Insulin Aspart Compared with Insulin Aspart in the Medtronic 670G Hybrid Closed Loop System in Type 1 Diabetes: An Open Label Crossover Study","volume":"23","author":"Ozer","year":"2021","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"10.1016\/j.diabres.2022.110144_b0105","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1089\/dia.2020.0224","article-title":"Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: PRONTO-Pump Study","volume":"23","author":"Bode","year":"2021","journal-title":"Diabetes Technol Ther"},{"issue":"6","key":"10.1016\/j.diabres.2022.110144_b0110","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/dom.14355","article-title":"Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study","volume":"23","author":"Boughton","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.diabres.2022.110144_b0115","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1089\/dia.2021.0184","article-title":"Ultrarapid Lispro Demonstrates Similar Time in Target Range to Lispro with a Hybrid Closed-Loop System","volume":"23","author":"Bode","year":"2021","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"10.1016\/j.diabres.2022.110144_b0120","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1089\/dia.2016.0350","article-title":"Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion","volume":"19","author":"Bode","year":"2017","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"10.1016\/j.diabres.2022.110144_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/dia.2020.0083","article-title":"Fast-Acting Insulin Aspart Use with the MiniMedTM670G System","volume":"23","author":"Hsu","year":"2021","journal-title":"Diabetes Technol Ther"},{"issue":"10","key":"10.1016\/j.diabres.2022.110144_b0130","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1111\/dom.14461","article-title":"Ultra-rapid-acting insulins for adults with diabetes: A systematic review and meta-analysis","volume":"23","author":"Avgerinos","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2022.110144_b0135","first-page":"1","article-title":"Performance of Fast-Acting Aspart Insulin as Compared to Aspart Insulin in Insulin Pump for Managing Type 1 Diabetes Mellitus: A Meta-Analysis","author":"Dutta","year":"2022","journal-title":"Diabetes Metab J"},{"issue":"5","key":"10.1016\/j.diabres.2022.110144_b0140","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40262-017-0514-8","article-title":"A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes","volume":"56","author":"Heise","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1016\/j.diabres.2022.110144_b0145","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1007\/s40262-021-01030-0","article-title":"Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs Humalog(\u00ae) Consistently Across Study Populations: A Pooled Analysis of Pharmacokinetic and Glucodynamic Data","volume":"60","author":"Leohr","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.diabres.2022.110144_b0150","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1089\/dia.2020.0360","article-title":"Impact of Fast-Acting Insulin Aspart on Glycemic Control in Patients with Type 1 Diabetes Using Intermittent-Scanning Continuous Glucose Monitoring within a Real-World Setting: The GoBolus Study","volume":"23","author":"Danne","year":"2021","journal-title":"Diabetes Technol Ther"},{"issue":"January","key":"10.1016\/j.diabres.2022.110144_b0155","first-page":"S73","article-title":"Glycemic targets: Standards of medical care in diabetes\u22122021","volume":"44","author":"Care","year":"2021","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.diabres.2022.110144_b0160","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1089\/dia.2010.0224","article-title":"Insulin Glulisine Compared to Insulin Aspart and to Insulin Lispro Administered by Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: A Randomized Controlled Trial","volume":"13","author":"Van Bon","year":"2011","journal-title":"Diabetes Technol Ther"},{"issue":"12","key":"10.1016\/j.diabres.2022.110144_b0165","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1007\/s13300-021-01160-5","article-title":"Hybrid Closed-Loop Systems for the Treatment of Type 1 Diabetes: A Collaborative, Expert Group Position Statement for Clinical Use in Central and Eastern Europe","volume":"12","author":"Janez","year":"2021","journal-title":"Diabetes Therapy"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822722009585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822722009585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:23:53Z","timestamp":1759173833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822722009585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":33,"alternative-id":["S0168822722009585"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2022.110144","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of ultra-rapid insulin analogues in insulin pumps in patients with Type 1 Diabetes Mellitus: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2022.110144","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110144"}}